# A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Study · id `cardio:ct-nct02415400` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02415400](<https://clinicaltrials.gov/study/NCT02415400>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02415400

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4614 participants.

## Technical summary

Registry record NCT02415400. Randomized; no masking; primary purpose other. Start 2015-06-04 (actual); primary completion 2018-11-10 (actual). Results posted on 2020-02-07.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Phase 4
- Enrolled: 4614 participants (enrolled count; ClinicalTrials.gov record NCT02415400, source copy `cardio:ctgov-nct02415400-2020-06-11`, retrieved 2026-10-31)
- Started: 2015-06-04 (actual) (ClinicalTrials.gov record NCT02415400, source copy `cardio:ctgov-nct02415400-2020-06-11`, retrieved 2026-10-31)
- Primary completion: 2018-11-10 (actual) (ClinicalTrials.gov record NCT02415400, source copy `cardio:ctgov-nct02415400-2020-06-11`, retrieved 2026-10-31)
- Completion: 2018-11-10 (actual) (ClinicalTrials.gov record NCT02415400, source copy `cardio:ctgov-nct02415400-2020-06-11`, retrieved 2026-10-31)
- Results first posted: 2020-02-07 (ClinicalTrials.gov record NCT02415400, source copy `cardio:ctgov-nct02415400-2020-06-11`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; Colombia; Croatia; Czechia; Denmark; France; Germany; Hungary; India; Israel; Italy; Mexico; Netherlands; Norway; Peru; Poland; Portugal; Puerto Rico; Romania; Russia; Serbia; Slovakia; South Korea; Spain; Sweden; Switzerland; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02415400, source copy `cardio:ctgov-nct02415400-2020-06-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02415400-2020-06-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
- Condition: Acute Coronary Syndromes
- Intervention (Drug): Apixaban
- Intervention (Drug): vitamin K antagonist
- Intervention (Drug): Acetylsalicylic acid
- Intervention (Other): Acetylsalicylic acid placebo
- Lead sponsor: Bristol-Myers Squibb
- Lead sponsor class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY
- Collaborator: Duke Clinical Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)
- Registry lists this organization as a collaborator: Duke Clinical Research Institute (`cardio:org-duke-clinical-research-institute`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation (`cardio:pubmed-30883055`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial (`cardio:pubmed-31557056`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial (`cardio:pubmed-35172988`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention (`cardio:pubmed-35115097`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial (`cardio:pubmed-35612866`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison From AUGUSTUS (`cardio:pubmed-39197976`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antithrombotic Strategies According to Age: Insights from the AUGUSTUS Trial (`cardio:pubmed-38876331`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial (`cardio:pubmed-39502066`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS (`cardio:pubmed-39557109`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS (`cardio:pubmed-39918467`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9562f7c4475d9cf002c6d1bfbc5ed8ca33826ee901046f646fcbae2cd25e7128
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
